Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease
Turkish Journal of Gastroenterology · 18.11.2026
DOI: 10.5152/tjg.2026.26709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, online erschienen am 18.11.2026. Verfasst von Jihye Park und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims: Few studies have analyzed the association between infliximab trough levels and clinical outcomes in patients with intestinal Behçet disease (BD). The authors investigated the role of infliximab trough levels as an independent predictive factor for clinical outcomes to infliximab in refractory intestinal BD. Materials and Methods: The authors analyzed 46 infliximab trough levels in 33 patients with intestinal BD between November 2019 and October 2025 at Severance Hospital, Seoul, South Korea. Clinical outcomes were compared between the high disease activity (n = 25) and normal or low disease activity (n = 21) groups.
Results
In 46 intestinal BD cases with a mean disease duration of 9.8 Å} 8.6 years and a mean infliximab treatment duration of 27.6 months, the infliximab trough level in the high disease activity group was 3.3 μg/mL, whereas it was 7.6 μg/mL in the normal or low disease activity group (P = .039). A mean infliximab level > 7.55 μg/mL (area under the receiver operating characteristic [AUROC]: 0.614, 95% CI: 0.451-0.718, P = .186) was associated with normal or low disease activity, although it did not reach statistical significance. Based on the multivariate logistic regression analysis results, the infliximab trough level was positively associated with normal or low disease activity in intestinal BD (odds ratio [OR]: 1.146, 95% CI: 1.004-1.309, P = .004). C-reactive protein levels (OR: 0.946, 95% CI: 0.904-0.991, P = .019) and the presence of systemic BD manifestations (OR: 0.003, 95% CI: 0.000-0.840, P = .043) were negatively associated with normal or low disease activity.
Conclusion
Higher infliximab trough levels were positively associated with normal or low disease activity to infliximab in intestinal BD. Cite this article as: Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of infliximab trough levels on clinical outcomes in patients with intestinal Behçet’s disease. Turk J Gastroenterol. Published online November 18, 2026. doi: 10.5152/tjg.2026.26709.
Zitieren
APA
Park, J., Mun, S. Y., Park, S. J., Park, J. J., Kim, T. I., & Cheon, J. H. (2026). Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2026.26709
Vancouver
Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease. Turkish Journal of Gastroenterology. 2026. doi:10.5152/tjg.2026.26709
BibTeX
@article{Park2026,
author = {Park, Jihye and Mun, Seo Young and Park, Soo Jung and Park, Jae Jun and Kim, Tae Il and Cheon, Jae Hee},
title = {Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease},
journal = {Turkish Journal of Gastroenterology},
year = {2026},
doi = {10.5152/tjg.2026.26709}
}
EUVIMED